Di Cesare A, Rosi E, Trovato E, et al. Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study. Dermatol Pract Concept. 2025;15(4):5733. doi:10.5826/dpc.1504a5733